Showing 6391-6400 of 8842 results for "".
- iovera Treatment Approved in Canadahttps://practicaldermatology.com/news/20130725-iovera_treatment_approved_in_canada/2459492/ioveradegrees received regulatory approval in Canada. Developed by myoscience, inc. in California, the ioveradegrees system targets forehead wrinkles using Focused Cold TherapyTM, a technology that helps to temporarily reduce the appearance of wrinkles without leaving any toxins or chemicals behind
- Galen Acquires Local Dermal Analgesia Drug Synerahttps://practicaldermatology.com/news/20130716-galen_acquires_local_dermal_analgesia_drug_synera/2459495/Galen, a Northern Ireland based pharmaceutical company, has acquired Synera® (lidocaine 70mg/tetracaine 70mg) topical patch from ZARS Pharma, Inc., a wholly owned subsidiary of Nuvo Research Inc. Synera® is indicated for use on intact skin t
- "What Not to Wear" Co-Host Partners with AbbVie on Psoriasis Campaignhttps://practicaldermatology.com/news/20130716-what_not_to_war_co-host_partners_with_abbvie_on_psoriasis_campaign/2459496/Stacy London, of TLC's "What Not to Wear," is partnering with AbbVie on a new psoriasis campaign called <a href="http://www.uncoveryourconfidence.com/">Uncover Your Confidence</a>. The campaign features educational resources and style advice for millions of Americans living with psoriasi
- European Commission Grants Conditional Approval to Erivedgehttps://practicaldermatology.com/news/20130716-european_commission_grants_conditional_approval_to_erivedge/2459497/The European Commission has granted conditional approval to Erivedge (vismodegib) for the treatment of adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery or radiotherapy. The Commission granted the conditional approval based upon t
- Sensus Healthcare Appoints Dr. Clay Cockerell as Medical Directorhttps://practicaldermatology.com/news/20130716-sensus_healthcare_appoints_dr_clay_cockerell_as_medical_director/2459498/Clay Cockerell, MD has been appointed Medical Director for the medical device company Sensus Healthcare. Dr. Cockerell will lead the Medical Advisory Board as the company continues to provide technology for non-invasive skin cancer treatment for non-melanoma skin cancer as well as treatment for kelo
- ASDS Database Helps Residents Find Fellowships and Opportunitieshttps://practicaldermatology.com/news/20130716-asds_database_helps_residents_find_fellowships_and_opportunities/2459499/To help residents with the challenge of identifying suitable fellowship programs, the American Society for Dermatologic Surgery's (ASDS) new database, called the DermSurg Fellowship Finder, is a comprehensive source for all Mohs, procedural, cosmetic, and laser surgical fellowships in the US. The go
- Investigational Psoriasis Agent On Track for Regulatory Submission This Yearhttps://practicaldermatology.com/news/20130708-investigational_psoriasis_agent_on_track_for_regulatory_submission_this_year/2459501/Results from a Phase III trial showed that the experimental drug secukinumab (Novartis) showed superiority to etanercept (Enbrel, Amgen) at clearing skin in patients with moderate-to-severe plaque psoriasis. The FIXTURE trial, which randomized 1,307 patients with moderate-to-severe plaque psoriasis,
- Merz North America Appoints New Vice Presidenthttps://practicaldermatology.com/news/20130702-merz_north_america_appoints_new_vice_president/2459503/Greg Besase has been appointed Vice President of Merz North America. Besase joined Merz in December 2012 as Director of Marketing, Dermatology and has served as the interim head of the U.S. Dermatology Business Unit since February 2013.
- Allergan Appoints Douglas S. Ingram as Presidenthttps://practicaldermatology.com/news/20130702-allergan_appoints_douglas_s_ingram_as_president/2459504/Douglas S. Ingram was appointed as President of Allergan. In this role, Mr. Ingram will lead the company's global commercial operations, with responsibility for the company's broad portfolio of pharmaceutical, consumer, and medical device product
- Naftin Gel 2% Approved for Interdigital-Type Tinea Pedishttps://practicaldermatology.com/news/20130702-naftin_gel_2_approved_for_interdigital-type_tinea_pedis/2459507/The FDA approved Naftin (naftifine HCl) Gel 2% for the treatment of interdigital-type tinea pedis from Merz North America. Naftin Gel 2% improves on the current formulation of Naftin Gel 1% by delivering the efficacy of naftifine hydochloride with